Search Results

AIA-PACK TSH 3rd-Gen is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of thyroid stimulating hormone (thyrotrophin) in human serum on TOSOH AIA System analyzers. Measurements obtained by human serum on TOSOH AIA Syste numan serum on 100017 M : System any of thyroid or pituitary disorders.

Not Found

It appears you've provided snippets from an FDA 510(k) clearance letter for the "AIA-PACK TSH 3rd-Gen Assay". This document is an FDA clearance letter, which confirms the device is substantially equivalent to a predicate device and can be marketed. It does not contain the detailed study information, acceptance criteria, or performance data that you've requested.

The FDA clearance letter primarily focuses on:

• Confirming the device's classification (Class II).
• Stating that it's substantially equivalent to a predicate device.
• Listing general controls and regulatory requirements.
• Providing contact information for various FDA offices.

To answer your specific questions (acceptance criteria, study details, sample sizes, ground truth, expert qualifications, etc.), you would typically need to refer to:

• The 510(k) summary document submitted by the manufacturer to the FDA, which often includes a summary of performance data.
• The full 510(k) submission, if publicly available or requested from the manufacturer, which would contain the detailed study protocols and results.
• Peer-reviewed publications related to the device.

Therefore, based only on the provided text, I cannot answer most of your detailed questions about the study design and acceptance criteria.

However, I can extract the following limited information:

• Device Name: AIA-PACK TSH 3rd-Gen Assay
• Intended Use: For IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of thyroid stimulating hormone (thyrotrophin) in human serum on TOSOH AIA System analyzers. Measurements obtained by human serum on TOSOH AIA Syste numan serum on 100017 M : System any of thyroid or pituitary disorders. (There appears to be a transcription error in the last part of this sentence in the provided document).
• Regulatory Class: II
• Product Code: JLW, JIS

To illustrate what you're asking for, if this were a document that did contain the information, here's how a hypothetical answer might appear, with placeholders for the actual data that is missing from your provided text:

Based on the typical structure of device clearance documentation, the following information would be found in the 510(k) summary or full submission. The provided FDA clearance letter does not contain these details directly.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample size used for the test set and the data provenance

• Test Set Sample Size: [Information not available in the provided document. Hypothetically: 200 patient samples]
• Data Provenance: [Information not available in the provided document. Hypothetically: Retrospective clinical samples from multiple hospitals in the USA and Europe]

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

• [Information not available in the provided document. Hypothetically: Ground truth for quantitative assays like TSH is typically based on reference method assays, not expert consensus on individual cases. For clinical interpretation studies, if applicable, it might be 3 board-certified endocrinologists with 15+ years of experience.]

4. Adjudication method for the test set

• [Information not available in the provided document. Not typically applicable for quantitative IVD performance studies, where ground truth is analytical.)

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance

• [Information not available in the provided document. This type of study (MRMC for AI assistance) is not generally relevant for a standalone in vitro diagnostic assay like a TSH test, which produces a quantitative result and does not involve human "readers" interpreting images or complex data in the same way an AI diagnostic imaging tool would. Performance is typically compared against a reference method or predicate device.]

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

• Yes, for an in vitro diagnostic assay, the performance metrics (sensitivity, precision, accuracy, linearity) evaluate the "algorithm only" or assay's performance in generating a quantitative result. The provided document indicates the device "AIA-PACK TSH 3rd-Gen is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement..." implying standalone performance testing. Specific details, however, are not in the provided text.

7. The type of ground truth used

• [Information not available in the provided document. For quantitative assays like TSH, ground truth is typically established by:
  • Reference method/gold standard assays: Using highly accurate and validated laboratory methods.
  • Validated calibrators: Traceable to international reference materials (e.g., WHO standards).
  • Clinical diagnosis/outcome correlation (for clinical utility studies): Though less direct for the assay's analytical ground truth.]

8. The sample size for the training set

• [Information not available in the provided document. In vitro diagnostic assays like this typically involve reagent and method development, calibration curve generation, and rigorous validation rather than a "training set" in the machine learning sense. However, if there were adaptable algorithms within the system, this information would be found in assay development details.]

9. How the ground truth for the training set was established

• [Information not available in the provided document. Refer to point 8 for context. Calibration and standardization are key for IVDs.]

Ask a specific question about this device